Barclays
CGON icon

Barclays’s CG Oncology CGON Stock Holding History

Barclays’s Portfolio CGON Stock Details CGON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.43M Buy
118,613
+107,114
+932% +$7M ﹤0.01% 1562
2026
Q1 		$778K Sell
11,499
-176,011
-94% -$9.97M ﹤0.01% 2902
2025
Q4 		$7.79M Buy
187,510
+33,555
+22% +$1.39M ﹤0.01% 1883
2025
Q3 		$6.2M Sell
153,955
-192,545
-56% -$5.6M ﹤0.01% 2026
2025
Q2 		$9.01M Buy
346,500
+253,961
+274% +$6.12M ﹤0.01% 1659
2025
Q1 		$2.27M Sell
92,539
-8,718
-9% -$245K ﹤0.01% 2541
2024
Q4 		$2.9M Buy
101,257
+10,737
+12% +$367K ﹤0.01% 2610
2024
Q3 		$3.42M Buy
90,520
+69,523
+331% +$2.44M ﹤0.01% 2404
2024
Q2 		$663K Buy
20,997
+4,644
+28% +$161K ﹤0.01% 2857
2024
Q1 		$718K Buy
+16,353
New +$668K ﹤0.01% 3353

Other funds holding CGON

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Barclays's CGON Position: Q2 2026 in Review

Barclays increased its CG Oncology (CGON) stake by 932% in Q2 2026, buying an estimated $7M and bringing the position to 118,613 shares worth $8.43M. The position accounts for ﹤0.01% of the portfolio, ranked #1562.

Barclays first reported a position in CGON in Q1 2024 and has held it in 10 quarters since. The position peaked at $9.01M in Q2 2025. 227 funds tracked by Wall St. Rank hold CGON as of Q2 2026.

  • Barclays held 118,613 shares of CG Oncology worth $8.43M as of Q2 2026.
  • Barclays bought 107,114 CG Oncology shares in Q2 2026, an estimated $7M.
  • CG Oncology made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #1562 holding.
  • Barclays first reported a position in CG Oncology in Q1 2024 and has held it in 10 quarters since.
  • Barclays's CG Oncology position peaked at $9.01M in Q2 2025.
  • 227 funds tracked by Wall St. Rank held CG Oncology as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.